Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.480.02%
QQQ
714.89-
BTC/USD
77222.000.0688%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Sarepta Therapeutics Inc

SRPTNASDAQ
Trade with Public
Trade with Public
$20.45
-0.07-0.34%
At close: Sep 11, 5:00 PM EST
$20.29
-0.16-0.78%
After Hours: Sep 11, 7:58 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Sarepta Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sarepta Therapeutics (SRPT).

Price Target Range — 6 Quarters

Analyst Consensus — 24 Analysts

9Buy
10Hold
5Sell
Consensus RatingOutperform# Analysts24Avg. Consensus PT$25Upside to Avg. PT+22.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 9, 2026Piper SandlerBiren AminPT CutNeutral$23→$20
Jul 9, 2026Wolfe ResearchAndy ChenUpgradePeer Perform→Outperform$27
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
Benzinga Newsdesk

PRO
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13

Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.
Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Sarepta Therapeutics, Maintains $37 Price Target

Oppenheimer analyst Kostas Biliouris reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $37 price target.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $31

Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $26 to $31.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved